DK1212323T3 - Substituerede pyridino-pentaazamakrocykluskomplekser med superoxid-dismutaseaktivitet - Google Patents

Substituerede pyridino-pentaazamakrocykluskomplekser med superoxid-dismutaseaktivitet

Info

Publication number
DK1212323T3
DK1212323T3 DK00966722T DK00966722T DK1212323T3 DK 1212323 T3 DK1212323 T3 DK 1212323T3 DK 00966722 T DK00966722 T DK 00966722T DK 00966722 T DK00966722 T DK 00966722T DK 1212323 T3 DK1212323 T3 DK 1212323T3
Authority
DK
Denmark
Prior art keywords
complexes
pentaazamacrocycle
superoxide dismutase
dismutase activity
substituted pyridino
Prior art date
Application number
DK00966722T
Other languages
Danish (da)
English (en)
Inventor
James A Sikorski
Dennis Riley
William L Neumann
Susan L Henke
Patrick Lennon
Daniela Salvemini
Yvette Fobian
Carrie L Kusturin
Karl W Aston
Margaret L Grapperhaus
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of DK1212323T3 publication Critical patent/DK1212323T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00966722T 1999-09-16 2000-09-14 Substituerede pyridino-pentaazamakrocykluskomplekser med superoxid-dismutaseaktivitet DK1212323T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/398,120 US6214817B1 (en) 1997-06-20 1999-09-16 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
PCT/US2000/025154 WO2001019823A2 (en) 1999-09-16 2000-09-14 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity

Publications (1)

Publication Number Publication Date
DK1212323T3 true DK1212323T3 (da) 2004-10-25

Family

ID=23574065

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00966722T DK1212323T3 (da) 1999-09-16 2000-09-14 Substituerede pyridino-pentaazamakrocykluskomplekser med superoxid-dismutaseaktivitet

Country Status (12)

Country Link
US (1) US6214817B1 (pt)
EP (3) EP1420022B1 (pt)
JP (2) JP2003509423A (pt)
AT (3) ATE368039T1 (pt)
AU (1) AU784078B2 (pt)
CA (1) CA2382105C (pt)
DE (3) DE60035724T2 (pt)
DK (1) DK1212323T3 (pt)
ES (3) ES2222925T3 (pt)
HK (1) HK1046689B (pt)
PT (1) PT1212323E (pt)
WO (1) WO2001019823A2 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
EP0846003A1 (en) * 1995-08-17 1998-06-10 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
EP1616869B1 (en) 1999-01-25 2012-04-04 National Jewish Health Substituted porphyrins and their therapeutic use
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
DE60235955D1 (de) * 2001-01-05 2010-05-27 Metaphore Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
CA2436245C (en) 2001-01-19 2013-04-23 National Jewish Medical And Research Center Medicament for protection in radiotherapy
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
WO2002071054A1 (en) * 2001-03-02 2002-09-12 Metaphore Pharmaceuticals, Inc. Chromatography of metal complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
EP1439842A4 (en) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
JP2005518334A (ja) * 2001-06-08 2005-06-23 メタファー・ファーマシューティカルズ・インコーポレイテッド コンホーメーション的に束縛されたペプチド、キラルアザクラウンおよびペプチド模倣物のライブラリーならびにその製造方法
MXPA03011795A (es) * 2001-06-26 2005-10-18 Metaphore Pharmaceuticals Inc Terapia de combinacion de una superoxido dismutasa mimetica y un corticosteroide para la prevencion y/o el tratamiento de una enfermedad inflamatoria.
US20040132706A1 (en) * 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
CN101092432A (zh) * 2001-12-14 2007-12-26 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
US7485721B2 (en) * 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
AU2003298917A1 (en) * 2002-12-06 2004-06-30 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
AU2004305531B2 (en) * 2003-12-11 2009-11-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
US7885698B2 (en) * 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
DK2056675T3 (en) 2006-10-12 2019-04-23 Galera Labs Llc Methods for treating oral mucositis
WO2008114017A2 (en) * 2007-03-19 2008-09-25 Imperial Innovations Limited Compositions and methods relating to influenza infection
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
WO2010022388A2 (en) * 2008-08-22 2010-02-25 Novomer, Inc. Catalysts and methods for polymer synthesis
US20120111756A1 (en) * 2008-12-17 2012-05-10 Altheus Therapeutics, Inc. Enema formulations
US9149483B2 (en) 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20221914A1 (es) 2011-12-28 2022-12-23 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN105899132B (zh) 2013-12-31 2020-02-18 雅培糖尿病护理公司 自供电分析物传感器以及使用其的装置
AU2015214182B2 (en) 2014-02-07 2020-04-30 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN108350009B (zh) 2015-08-11 2021-07-09 加莱拉实验室有限责任公司 具有口服生物利用率的五氮杂大环状环络合物
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
AU2017318718B2 (en) * 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US20210361701A1 (en) * 2017-02-15 2021-11-25 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local delivery
MX2019012259A (es) * 2017-04-13 2020-02-26 Galera Labs Llc Inmunoterapia combinada contra el cancer con complejo de anillo pentaazamacrociclico.
IL269915B (en) 2017-04-13 2022-09-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN115260178A (zh) * 2022-08-09 2022-11-01 上海师范大学 一种吡啶骨架ncn噁唑啉类配体的合成方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
NO149961C (no) 1981-06-01 1984-07-25 Borregaard Ind Fremgangsmaate for fremstilling av n-(2-hydroksyetyl)-derivater av makrocykliske polyaminer, inneholdende flere nitrogenatomer i 1,4-forhold i ringen
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US4968616A (en) 1986-05-16 1990-11-06 Masayasu Inoue Superoxide dismutase derivatives, method of producing same and medicinal use of same
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
US5252720A (en) 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
WO1991010669A1 (en) 1990-01-19 1991-07-25 Cockbain, Julian, Roderick, Michaelson Chelating compounds
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
GB9024208D0 (en) 1990-11-07 1990-12-19 Salutar Inc Compounds
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0598753B1 (en) * 1991-07-19 1998-03-18 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1993011800A1 (en) 1991-12-10 1993-06-24 The Dow Chemical Company Bicycle-polyazamacrocyclocarboxylic acid complexes, conjugates, preparation and use as contrast agents
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
JPH10500401A (ja) 1994-04-22 1998-01-13 モンサント カンパニー 金属錯体を用いる診断画像解析法
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
JPH11507621A (ja) 1995-06-07 1999-07-06 モンサント カンパニー 置換ポリアザ大環状化合物の製造法
SE509595C2 (sv) * 1996-01-25 1999-02-15 Sandvik Ab Skär för spånavskiljande metallbearbetning
BR9708179A (pt) * 1996-03-13 1999-07-27 Monsanto Co Bioconjugados de complexos de manganês ou ferro de ligantes macrociclicos contendo nitrogênio eficazes como catalizadores para desmutar superoxidos
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Also Published As

Publication number Publication date
ATE366254T1 (de) 2007-07-15
ATE268774T1 (de) 2004-06-15
HK1046689B (zh) 2005-03-11
EP1420019B1 (en) 2007-07-25
CA2382105A1 (en) 2001-03-22
WO2001019823A9 (en) 2002-09-26
EP1212323A2 (en) 2002-06-12
WO2001019823A2 (en) 2001-03-22
US6214817B1 (en) 2001-04-10
DE60035440D1 (de) 2007-08-16
DE60035724T2 (de) 2008-04-30
PT1212323E (pt) 2004-10-29
DE60011446T2 (de) 2005-07-07
EP1212323B1 (en) 2004-06-09
DE60035724D1 (de) 2007-09-06
JP2012097097A (ja) 2012-05-24
DE60035440T2 (de) 2008-03-13
EP1420019A1 (en) 2004-05-19
AU784078B2 (en) 2006-02-02
HK1046689A1 (en) 2003-01-24
DE60011446D1 (de) 2004-07-15
CA2382105C (en) 2012-01-10
AU7702400A (en) 2001-04-17
WO2001019823A3 (en) 2001-09-07
ES2291759T3 (es) 2008-03-01
ES2293106T3 (es) 2008-03-16
EP1420022B1 (en) 2007-07-04
EP1420022A1 (en) 2004-05-19
JP2003509423A (ja) 2003-03-11
ES2222925T3 (es) 2005-02-16
ATE368039T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
DK1212323T3 (da) Substituerede pyridino-pentaazamakrocykluskomplekser med superoxid-dismutaseaktivitet
DE60012571D1 (de) Metallkomplexe als hyrdosilylierungskatalysatoren
AU2002360982A1 (en) Support-fixed bleaching catalyst complex compounds suitable as catalysts for peroxide compounds
ATE511222T1 (de) Komplex der formel l2irx
AU5964894A (en) Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
MY127285A (en) Ruthenium complexes as (pre)catalysts for metathesis reactions
IL102408A0 (en) Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
ATE467413T1 (de) Oxindolderivate als antikrebsmittel
TR200003273A2 (tr) Olefinler'den katalitik olarak aldehit imalatına yönelik usul
AU6023796A (en) Manganese or iron complexes of nitrogen-containing macrocycl ic ligands effective as catalysts for dismutating superoxide
WO2006134174A3 (en) Dimeric and multimeric fviia compound
NO972726D0 (no) Tricykliske forbindelser
BR0315869A (pt) Uso de compostos de complexos de metais como catalisadores de oxidação
AU2003240732A1 (en) Use of transition metal complexes with nitrogen-containing polydentate ligands as a bleaching catalyst and bleaching agent composition
ATE517626T1 (de) Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen
DE602004002114D1 (de) Substituierte ferrocenyldiphosphinligande für homogene hydrogenieringskatalysatoren
NO984164D0 (no) Biokonjugater av mangan eller jernkomplekser bestående av nitrogen-inneholdende makrocykliske ligander effektive som katalysatorer for dismutering av superoksid
WO2002058686A3 (en) Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
WO2003059510A3 (en) Manganese(iv) complex salts and their use as oxidation catalysts
NO982240D0 (no) FremgangsmÕte ved oksidering av organiske substrater i nµrvµr av metallkomplekser av tetra-, penta-, og heksakooridinerte ligander, samt oksidasjonskatalysatorer inneholdende disse
BG103520A (en) The use of aminothiazoles as microbicides
ATE344264T1 (de) Porphyrin-verbindung, deren albumin- einschlussverbindung und künstlicher sauerstoffträger
ES2159087T3 (es) Oxindoles sustituidos con adamantilo como agentes farmaceuticos.
RU93019809A (ru) Тетрофтортетраазапорфин